Immediate Impact

1 from Science/Nature 52 standout
Sub-graph 1 of 24

Citing Papers

Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
2024 Standout
Rheumatoid arthritis: pathogenesis and therapeutic advances
2024 Standout
2 intermediate papers

Works of G. Armstrong being referenced

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
2010
Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
2010
and 1 more

Author Peers

Author Last Decade Papers Cites
G. Armstrong 157 27 45 353 142 24 671
Jeffrey B. Shiroky 90 6 21 386 139 16 647
A M M Eijsbouts 106 46 26 404 99 16 723
H. C. M. Haanen 81 26 26 517 197 13 820
Y Schenk 134 24 64 580 247 14 776
A. A. M. Blaauw 124 27 45 568 255 15 753
Kok Yong Fong 48 26 48 284 148 42 786
David Walker 123 19 69 454 236 52 711
Alice Klinkhoff 51 52 16 490 158 30 788
Amir Emamifar 104 24 14 370 125 36 613
H.L.M. Brus 101 28 11 466 188 18 585

All Works

Loading papers...

Rankless by CCL
2026